Nicole Daver, DO
Internal Medicine · Summit, NJNPI 1629205067
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by GSK at 49.1% of the total. Reporting peaked in 2022 at $4,621 and has fallen 64.9% since, to $1,624 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- Novartis$1K
- Amgen$1K
- AbbVie$852
- Johnson & Johnson$727
- Pfizer$556
- plus $2K from 22 others
What the payments were for
- Consulting fees$5,68542%
- Food & beverage$7,50356%
- Education$2722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $6,607 |
| Novartis | 62 | $1,148 |
| Amgen(2 entities) | 78 | $1,135 |
| AbbVie | 60 | $852 |
| Johnson & Johnson(2 entities) | 43 | $727 |
| Pfizer | 35 | $556 |
| E.r. Squibb & Sons, L.L.C. | 33 | $468 |
| UCB, Inc. | 23 | $389 |
| Mallinckrodt Hospital Products Inc. | 8 | $218 |
| AstraZeneca(2 entities) | 12 | $191 |
| Sanofi | 8 | $140 |
| Organon | 8 | $140 |
| Boehringer Ingelheim | 9 | $133 |
| Lilly USA, LLC | 9 | $128 |
| Pacira Therapeutics, Inc. | 6 | $91 |
| Bioventus LLC | 3 | $83 |
| Sobi, Inc | 5 | $78 |
| Genentech USA, Inc. | 4 | $61 |
| Hikma Pharmaceuticals USA | 4 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $48 |
| Bristol Myers Squibb | 3 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $43 |
| Radius Health, Inc. | 2 | $38 |
| Sebela Pharmaceuticals Inc. | 2 | $26 |
| Sandoz | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$5,807
How this compares
$13,460 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 56 | $403,198 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 43 | $314,971 |
| Enbrel SureclickEtanercept | 27 | $233,327 |
| Xeljanz XrTofacitinib Citrate | 31 | $189,808 |
| RinvoqUpadacitinib | 23 | $158,816 |
| OrenciaAbatacept | 19 | $125,478 |
| BenlystaBelimumab | 23 | $120,570 |
| Actemra ActpenTocilizumab | 27 | $113,197 |
| ActemraTocilizumab | 14 | $96,791 |
| EnbrelEtanercept | 12 | $86,659 |
| HumiraAdalimumab | 12 | $83,496 |
| OtezlaApremilast | 14 | $66,407 |
| Orencia ClickjectAbatacept | 12 | $65,856 |
| KineretAnakinra | 12 | $65,720 |
| RasuvoMethotrexate/Pf | 25 | $13,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $852 | $242,31235 claims |
| AmgenEnbrel, Otezla | $1,135 | $153,06626 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $468 | $125,47819 claims |
| GSKBenlysta | $6,607 | $120,57023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Summit
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.